ProBNP‐derived peptides in cardiac disease

References

• Kisch B. A Significant electron microscopic difference between the atria and the ventricles of the mammalian heart. Exp Med Surg 1963; 21: 193–221.
   PubMedGoogle Scholar
• Jamieson JD, Palade GE. Specific granules in atrial muscle cells. J Cell Biol 1964; 23: 151–72.
   PubMed Web of Science ®Google Scholar
• de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myo-cardial extract in rats. Life Sci 1981; 28: 89–94.
   PubMed Web of Science ®Google Scholar
• de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Reprinted from Life Sci 28: 89-94, 1981. J Am Soc Nephrol 2001; 12: 403–9.
   Google Scholar
• Flynn TG, de Bold ML, de Bold AJ. The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties. Biochem Bio-phys Res Commun 1983; 117: 859–65.
   PubMed Web of Science ®Google Scholar
• de Bold AJ, Flynn TG. Cardionatrin I—a novel heart peptide with potent diuretic and natriuretic properties. Life Sci 1983; 33: 297–302.
   PubMed Web of Science ®Google Scholar
• Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988; 332: 78–81.
   PubMed Web of Science ®Google Scholar
• Minamino N, Aburaya M, Ueda S, Kangawa K, Matsuo H. The presence of brain natriuretic peptide of 12,000 daltons in porcine heart. Biochem Biophys Res Commun 1988; 155: 740–6.
   PubMed Web of Science ®Google Scholar
• Saito Y, Nakao K, Itoh H, Yamada T, Mukoyama M, Arai H, Hosoda K, Shirakami G, Suga S, Minamino N. Brain natriuretic peptide is a novel cardiac hormone. Biochem Biophys Res Commun 1989; 158: 360–8.
   PubMed Web of Science ®Google Scholar
• Kambayashi Y, Nakao K, Mukoyama M, Saito Y, Ogawa Y, Shiono S, Inouye K, Yoshida N, Imura H. Isolation and sequence determination of human brain natriuretic peptide in human atrium. FEBS Lett 1990; 259: 341–5.
   Google Scholar
• Hino J, Tateyama H, Minamino N, Kangawa K, Matsuo H. Isolation and identification of human brain natriuretic peptides in cardiac atrium. Biochem Biophys Res Commun 1990; 167: 693–700.
   PubMed Web of Science ®Google Scholar
• Drewett JG, Garbers DL. The family of guanylyl cyclase receptors and their ligands. Endocr Rev 1994; 15: 135–62.
   PubMed Web of Science ®Google Scholar
• Sudoh T, Minamino N, Kangawa K, Matsuo H. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun 1990; 168: 863— 70.
   PubMed Web of Science ®Google Scholar
• Kalra PR, Anker SD, Struthers AD, Coats AJ. The role of C-type natriuretic peptide in cardio-vascular medicine. Eur Heart J 2001; 22: 997 — 1007.
   PubMed Web of Science ®Google Scholar
• de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362: 316–22.
   Google Scholar
• Liang F, Gardner DG. Mechanical strain activates BNP gene transcription through a p38/NF-kappaB-dependent mechanism. J Clin Invest 1999; 104: 1603–12.
   PubMed Web of Science ®Google Scholar
• Hanford DS, Thuerauf DJ, Murray SF, Glembotski CC. Brain natriuretic peptide is induced by alpha 1-adrenergic agonists as a primary response gene in cultured rat cardiac myocytes. J Biol Chem 1994; 269: 26227–33.
   PubMed Web of Science ®Google Scholar
• Liang F, Gardner DG. Autocrine/paracrine deter-minants of strain-activated brain natriuretic pep-tide gene expression in cultured cardiac myocytes. J Biol Chem 1998; 273: 14612–9.
   PubMed Web of Science ®Google Scholar
• Wiese S, Breyer T, Dragu A, Wakili R, Burkard T, Schmidt-Schweda S, Fuchtbauer EM, Dohrmann U, Beyersdorf F, Radicke D, Holubarsch CJ. Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and diastolic fiber length. Circulation 2000; 102: 3074–9.
   Google Scholar
• Frey N, McKinsey TA, Olson EN. Decoding calcium signals involved in cardiac growth and function. Nat Med 2000; 6: 1221–7.
   Google Scholar
• Kudoh S, Akazawa H, Takano H, Zou Y, Toko H, Nagai T, Komuro I. Stretch-modulation of second messengers: effects on cardiomyocyte ion transport. Prog Biophys Mol Biol 2003; 82: 57 — 66.
   Google Scholar
• Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998; 93: 215–28.
   PubMed Web of Science ®Google Scholar
• Zhu W, Zou Y, Shiojima I, Kudoh S, Aikawa R, Hayashi D, Mizukami M, Toko H, Shibasaki F, Yazaki Y, Nagai R, Komuro I. Ca2 + /calmodulin-dependent kinase II and calcineurin play critical roles in endothelin-l-induced cardiomyocyte hypertrophy. J Biol Chem 2000; 275: 15239–45.
   PubMed Web of Science ®Google Scholar
• Richards AM, Doughty R, Nicholls MG, MacMahon S, Sharpe N, Murphy J, Espiner EA, Frampton C, Yandle TG. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction.Australia-New Zealand Heart Failure Group J Am Coll Cardiol 2001; 37: 1781–7.
   Google Scholar
• Stanek B, Frey B, Hulsmann M, Berger R, Sturm B, Strametz-Juranek J, Bergler-Klein J, Moser P, Bojic A, Hartter E, Pacher R. Prognostic evalua-tion of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 2001; 38: 436–42.
   Google Scholar
• Latini R, Masson S, Anand I, Judd D, Maggioni AP, Chiang YT, Bevilacqua M, Salio M, Cardano P, Dunselman PH, Holwerda NJ, Tognoni G, Cohn JN. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in sympto-matic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002; 106: 2454 — 8.
   Google Scholar
• Hanford DS, Glembotski CC. Stabilization of the B-type natriuretic peptide mRNA in cardiac myocytes by alpha-adrenergic receptor activation: potential roles for protein kinase C and mitogen-activated protein kinase. Mol Endocrinol 1996; 10: 1719 — 27.
   PubMedGoogle Scholar
• Chun YS, Hyun JY, Kwak YG, Kim IS, Kim CH, Choi E, Kim MS, Park JW. Hypoxic activation of the atrial natriuretic peptide gene promoter through direct and indirect actions of hypoxia-inducible factor-1. Biochem J 2003; 370: 149–57.
   PubMed Web of Science ®Google Scholar
• Semenza GL. Targeting HIF-1 for cancer therapy. Natl Rev Cancer 2003; 3: 721–32.
   PubMed Web of Science ®Google Scholar
• Semenza GL. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 2000; 35: 71–103.
   PubMed Web of Science ®Google Scholar
• Jiang C, Lu H, Vincent KA, Shankara S, Belanger AJ, Cheng SH, Akita GY, Kelly RA, Goldberg MA, Gregory RJ. Gene expression profiles in human cardiac cells subjected to hypoxia or expressing a hybrid form of HIF-1 alpha. Physiol Genomics 2002; 8: 23–32.
   PubMed Web of Science ®Google Scholar
• Perhonen M, Takala TE, Vuolteenaho 0, Mantymaa P, Leppaluoto J, Ruskoaho H. Induc-tion of cardiac natriuretic peptide gene expression in rats trained in hypobaric hypoxic conditions. Am J Physiol 1997; 273: R344 —R52.
   Google Scholar
• Toth M, Vuorinen KH, Vuolteenaho 0, Hassinen IE, Uusimaa PA, Leppaluoto J, Ruskoaho H. Hypoxia stimulates release of ANP and BNP from perfused rat ventricular myocardium. Am J Physiol 1994; 266: H1572— H80.
   Google Scholar
• de Bold AJ, Ma KK, Zhang Y, de Bold ML, Bensimon M, Khoshbaten A. The physiological and pathophysiological modulation of the endo-crine function of the heart. Can J Physiol Pharmacol 2001; 79: 705–14.
   Google Scholar
• Christoffersen C, Goetze JP, Bartels ED, Larsen MO, Ribel U, Rehfeld JF, Rolin B, Nielsen LB. Chamber-dependent expression of brain natriure-tic peptide and its mRNA in normal and diabetic pig heart. Hypertension 2002; 40: 54–60.
   PubMed Web of Science ®Google Scholar
• Hasegawa K, Fujiwara H, Doyama K, Mukoyama M, Nakao K, Fujiwara T, Imura H, Kawai C. Ventricular expression of atrial and brain natriuretic peptides in dilated cardiomyo-pathy. An immunohistocytochemical study of the endomyocardial biopsy specimens using specific monoclonal antibodies. Am J Pathol 1993; 142: 107–16.
   Google Scholar
• Nicolau N, Butur G, Laky D. Electronmicroscopic observations regarding the presence of natriuretic granules in the ventricle of patients with cardio-pathies. Rom J Morphol Embryol 1997; 43: 119–37.
   Google Scholar
• Takemura G, Takatsu Y, Doyama K, Itoh H, Saito Y, Koshiji M, Ando F, Fujiwara T, Nakao K, Fujiwara H. Expression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosis. J Am Coll Cardiol 1998; 31: 754–65.
   PubMed Web of Science ®Google Scholar
• Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, Shirakami G, Jougasaki M, Obata K, Yasue H. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87: 1402–12.
   Google Scholar
• Richards AM, Crozier IG, Holmes SJ, Espiner EA, Yandle TG, Frampton C. Brain natriuretic peptide: natriuretic and endocrine effects in essential hypertension. J Hypertens 1993; 11: 163–70.
   PubMed Web of Science ®Google Scholar
• Smith MW, Espiner EA, Yandle TG, Charles CJ, Richards AM. Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase. J Endocrinol 2000; 167: 239 —46.
   Google Scholar
• Burnett JC. Vasopeptidase inhibition. CUff Opin Nephrol Hypertens 2000; 9: 465–8.
   PubMed Web of Science ®Google Scholar
• Worthley MI, Corti R, Worthley SG. Vasopepti-dase inhibitors: will they have a role in clinical practice? Br J Clin Pharmacol 2004; 57: 27–36.
   Google Scholar
• Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, Suda M, Kasahara M, Hashimoto R, Katsuura G, Mukoyama M, Itoh H, Saito Y, Tanaka I, Otani H, Katsuki M. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA 2000; 97: 4239–44.
   PubMed Web of Science ®Google Scholar
• Ellmers LJ, Knowles JW, Kim HS, Smithies O, Maeda N, Cameron VA. Ventricular expression of natriuretic peptides in Nprl(-/-) mice with cardiac hypertrophy and fibrosis. Am J Physiol Heart Circ Physiol 2002; 283: H707 — H14.
   Web of Science ®Google Scholar
• Kapoun AM, Liang F, O'Young G, Damm DL, Quon D, White RT, Munson K, Lam A, Schreiner GF, Protter AA. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res 2004; 94: 453–61.
   Google Scholar
• Totsune K, Takahashi K, Satoh F, Sone M, Ohneda M, Satoh C, Murakami 0, Mouri T. Urinary immunoreactive brain natriuretic peptide in patients with renal disease. Regul Pept 1996; 63: 141–7.
   Google Scholar
• Ng LL, Geeranavar S, Jennings SC, Loke I, O'Brien RJ. Diagnosis of heart failure using urinary natriuretic peptides. Clin Sci (Lond) 2004; 106: 129–33.
   Google Scholar
• Henriksen JH, Goetze JP, Fuglsang S, Christensen E, Bendtsen F, Moller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrho-sis: relation to cardiovascular dysfunction and severity of disease. Gut 2003; 52: 1511–7.
   PubMed Web of Science ®Google Scholar
• Hunt PJ, Yandle TG, Nicholls MG, Richards AM, Espiner EA. The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochem Biophys Res Commun 1995; 214: 1175–83.
   Google Scholar
• Schulz H, Langvik TA, Lund SE, Smith J, Ahmadi N, Hall C. Radioimmunoassay for N-terminal probrain natriuretic peptide in human plasma. Scand J Clin Lab Invest 2001; 61: 33–42.
   PubMed Web of Science ®Google Scholar
• Goetze JP, Kastrup J, Pedersen F, Rehfeld JF. Quantification of pro-B-type natriuretic peptide and its products in human plasma by use of an analysis independent of precursor processing. Clin Chem 2002; 48: 1035–42.
   PubMed Web of Science ®Google Scholar
• Shimizu H, Masuta K, Asada H, Sugita K, Sairenji T. Characterization of molecular forms of probrain natriuretic peptide in human plasma. Clin Chim Acta 2003; 334: 233–9.
   Google Scholar
• Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf) 1997; 47: 287–96.
   PubMed Web of Science ®Google Scholar
• Goetze JP, Rehfeld JF, Videbaek R, Friis-Hansen L, Kastrup J. B-type natriuretic peptide and its precursor in cardiac venous blood from failing hearts. Eur J Heart Fail. In press.
   Google Scholar
• Pemberton CJ, Johnson ML, Yandle TG, Espiner EA. Deconvolution analysis of cardiac natriuretic peptides during acute volume overload. Hyperten-sion 2000; 36: 355–9.
   PubMed Web of Science ®Google Scholar
• Bristow MR, Zisman LS, Lowes BD, Abraham WT, Badesch DB, Groves BM, Voelkel NF, Lynch DM, Quaife RA. The pressure-overloaded right ventricle in pulmonary hypertension. Chest 1998; 114: 101S–6S.
   Google Scholar
• Nootens M, Kaufmann E, Rector T, Toher C, Judd D, Francis GS, Rich S. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemo-dynamic variables and endothelin levels. J Am Coll Cardiol 1995; 26: 1581–5.
   Google Scholar
• Nagaya N, Nishikimi T, Okano Y, Uematsu M, Satoh T, Kyotani S, Kuribayashi S, Hamada S, Kakishita M, Nakanishi N, Takamiya M, Kunieda T, Matsuo H, Kangawa K. Plasma brain natriuretic peptide levels increase in propor-tion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998; 31: 202–8.
   PubMed Web of Science ®Google Scholar
• Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Kakishita M, Fukushima K, Okano Y, Nakanishi N, Miyatake K, Kangawa K. Plasma brain natriuretic peptide as a prog-nostic indicator in patients with primary pulmon-ary hypertension. Circulation 2000; 102: 865–70.
   PubMed Web of Science ®Google Scholar
• Leuchte HH, Holzapfel M, Baumgartner RA, Ding I, Neurohr C, Vogeser M, Kolbe T, Schwaiblmair M, Behr J. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004; 43: 764 — 70.
   Google Scholar
• Tulevski II, Hirsch A, Sanson BJ, Romkes H, van der Wall EE, van Veldhuisen DJ, Buller HR, Mulder BJ. Increased brain natriuretic peptide as a marker for right ventricular dysfunction in acute pulmonary embolism. Thromb Haemost 2001; 86: 1193— 6.
   Google Scholar
• Tulevski II, Mulder BJ, van Veldhuisen DJ. Utility of a BNP as a marker for RV dysfunction in acute pulmonary embolism. J Am Coll Cardiol 2002; 39: 2080.
   Google Scholar
• Pruszczyk P, Kostrubiec M, Bochowicz A, Styczynski G, Szulc M, Kurzyna M, Fijalkowska A, Kuch-Wocial A, Chlewicka I, Torbicki A. N-terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism. Eur Respir J 2003; 22: 649–53.
   Google Scholar
• Ten Wolde M, Tulevski II, Mulder JW, Sohne M, Boomsma F, Mulder BJ, Buller HR. Brain natriuretic peptide as a predictor of adverse outcome in patients with pulmonary embolism. Circulation 2003; 107: 2082–4.
   Google Scholar
• Kucher N, Printzen G, Doernhoefer T, Windecker S, Meier B, Hess OM. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation 2003; 107: 1576— 8.
   PubMed Web of Science ®Google Scholar
• Nagaya N, Ando M, Oya H, Ohkita Y, Kyotani S, Sakamaki F, Nakanishi N. Plasma brain natriuretic peptide as a noninvasive marker for efficacy of pulmonary thromboendarterectomy. Ann Thorac Surg 2002; 74: 180–4.
   Google Scholar
• Goetze JP, Videbaek R, Boesgaard S, Aldershvile J, Rehfeld JF, Carlsen J. Pro-brain natriuretic peptide as marker of cardiovascular or pulmonary causes of dyspnea in patients with terminal parenchymal lung disease. J Heart Lung Trans-plant 2004; 23: 80–7.
   PubMed Web of Science ®Google Scholar
• Packer M. Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure? Circulation 2003; 108: 2950— 3.
   PubMed Web of Science ®Google Scholar
• Muders F, Kromer EP, Griese DP, Pfeifer M, Hense HW, Riegger GA, Elsner D. Evaluation of plasma natriuretic peptides as markers for left ventricular dysfunction. Am Heart J 1997; 134: 442 — 9.
   Google Scholar
• Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Sutton GC. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1349–53.
   Google Scholar
• McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, Tunstall-Pedoe H, McMurray JJ, Dargie HJ. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351: 9–13.
   Google Scholar
• McClure SJ, Caruana L, Davie AP, Goldthorp S, McMurray JJ. Cohort study of plasma natriuretic peptides for identifying left ventricular systolic dysfunction in primary care. Br Med J 1998; 317: 516 — 9.
   Google Scholar
• Luchner A, Burnett JC, Jr, Jougasaki M, Hense HW, Heid IM, Muders F, Riegger GA, Schunkert H. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hyper-trophy in the population. J Hypertens 2000; 18: 1121— 8.
   Google Scholar
• Bay M, Kirk V, Parner J, Hassager C, Nielsen H, Krogsgaard K, Trawinski J, Boesgaard S, Aldershvile J. NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. Heart 2003; 89: 150–4.
   Google Scholar
• Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Due P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161–7.
   PubMed Web of Science ®Google Scholar
• Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS. Plasma natriuretic peptide levels and the risk of cardio-vascular events and death. N Engl J Med 2004; 350: 655–63.
   PubMed Web of Science ®Google Scholar
• Cowie MR, Jourdain P, Maisel A, Dahlstrom U, Follath F, Isnard R, Luchner A, McDonagh T, Mair J, Nieminen M, Francis G. Clinical applica-tions of B-type natriuretic peptide (BNP) testing. Eur Heart J 2003; 24: 1710–8.
   PubMed Web of Science ®Google Scholar
• Davis M, Espiner E, Richards G, Billings J, Town I, Neill A, Drennan C, Richards M, Turner J, Yandle T. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 1994; 343: 440–4.
   PubMed Web of Science ®Google Scholar
• Dao Q, Krishnaswamy P, Kazanegra R, Harrison A, Amirnovin R, Lenert L, Clopton P, Alberto J, Hlavin P, Maisel AS. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001; 37: 379–85.
   PubMed Web of Science ®Google Scholar
• Cabanes L, Richaud-Thiriez B, Fulla Y, Heloire F, Vuillemard C, Weber S, Dusser D. Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea. Chest 2001; 120: 2047–50.
   PubMed Web of Science ®Google Scholar
• Harrison A, Morrison LK, Krishnaswamy P, Kazanegra R, Clopton P, Dao Q, Hlavin P, Maisel AS. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 2002; 39: 131–8.
   PubMed Web of Science ®Google Scholar
• Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002; 39: 202–9.
   PubMed Web of Science ®Google Scholar
• Knudsen CW, Omland T, Clopton P, Westheim A, Abraham WT, Storrow AB, McCord J, Nowak RM, Aumont MC, Due P, Hollander JE, Wu AH, McCullough PA, Maisel AS. Diagnostic value of B-type natriuretic peptide and chest radiographic findings in patients with acute dyspnea. Am J Med 2004; 116: 363–8.
   PubMed Web of Science ®Google Scholar
• Mueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P, Pfisterer M, Perruchoud AP. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004; 350: 647–54.
   Google Scholar
• Nielsen OW, McDonagh TA, Robb SD, Dargie HJ. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol 2003; 41: 113–20.
   PubMed Web of Science ®Google Scholar
• Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, Matsumura T, Mukoyama M, Nakao K. Increased plasma levels of brain natriuretic peptide in patients with acute myocar-dial infarction. Circulation 1993; 88: 82–91.
   PubMed Web of Science ®Google Scholar
• Nagaya N, Nishikimi T, Goto Y, Miyao Y, Kobayashi Y, Morii I, Daikoku S, Matsumoto T, Miyazaki S, Matsuoka H, Takishita S, Kangawa K, Matsuo H, Nonogi H. Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. Am Heart J 1998; 135: 21 — 8.
   PubMed Web of Science ®Google Scholar
• Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG, Buttimore RC, Lainchbury JG, Elliott JM, Ikram H, Crozier IG, Smyth DW. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular func-tion and prognosis after myocardial infarction. Circulation 1998; 97: 1921–9.
   PubMed Web of Science ®Google Scholar
• Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, Frampton C, Turner J, Crozier IG, Yandle TG. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circula-tion 2003; 107: 2786–92.
   PubMed Web of Science ®Google Scholar
• Tapanainen JM, Lindgren KS, Makikallio TH, Vuolteenaho 0, Leppaluoto J, Huikuri HV. Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the beta-blocking era. J Am Coll Cardiol 2004; 43: 757–63.
   Google Scholar
• Gill D, Seidler T, Troughton RW, Yandle TG, Frampton CM, Richards M, Lainchbury JG, Nicholls G. Vigorous response in plasma N-terminal pro-brain natriuretic peptide (NT-BNP) to acute myocardial infarction. Clin Sci (Lond) 2004; 106: 135–9.
   PubMed Web of Science ®Google Scholar
• Zeller M, Cottin Y, Laurent Y, Danchin N, L'Huillier I, Collin B, Desgres J, Ravisy J, Janin-Manificat L, Makki H, Jolak M, Beer JC, Dentan G, Gambert P, Wolf JE. N-terminal pro-brain natriuretic peptide levels in patients with non-ST-elevation myocardial infarction. Cardiology 2004; 102: 37–40.
   Google Scholar
• Kikuta K, Yasue H, Yoshimura M, Morita E, Sumida H, Kato H, Kugiyama K, Ogawa H, Okumura K, Ogawa Y, Nakao K. Increased plasma levels of B-type natriuretic peptide in patients with unstable angina. Am Heart J 1996; 132: 101–7.
   Google Scholar
• Talwar S, Squire IB, Downie PF, Davies JE, Ng LL. Plasma N terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina. Heart 2000; 84: 421–4.
   Google Scholar
• de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, Hall C, Cannon CP, Braunwald E. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345: 1014— 21.
   Google Scholar
• Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J, Hartford M, Caidahl K. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circula-tion 2002; 106: 2913–8.
   Google Scholar
• Omland T, de Lemos JA, Morrow DA, Antman EM, Cannon CP, Hall C, Braunwald E. Prog-nostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol 2002; 89: 463 — 5.
   PubMed Web of Science ®Google Scholar
• Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro-brain natriuretic peptide on admis-sion for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 2002; 40: 437–45.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, McCabe C, Antman EM, Cannon CP, Braunwald E. Multi-marker approach to risk stratification in non-ST elevation acute coronary syndromes: simulta-neous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circula-tion 2002; 105: 1760–3.
   PubMed Web of Science ®Google Scholar
• Deo R, de Lemos JA. B-type natriuretic peptide in ischemic heart disease. Curr Cardiol Rep 2003; 5: 271–7.
   PubMedGoogle Scholar
• Galvani M, Ferrini D, Ottani F. Natriuretic peptides for risk stratification of patients with acute coronary syndromes. Eur J Heart Fail 2004; 6: 327–33.
   Google Scholar
• Goetze JP, Yongzhong W, Rehfeld JF, Jorgensen E, Kastrup J. Coronary angiography transiently increases pro-B-type natriuretic peptide. Eur Heart J 2004; 25: 759–64.
   Google Scholar
• Goetze JP, Christoffersen C, Perko M, Arendrup H, Rehfeld JF, Kastrup J, Nielsen LB. Increased cardiac BNP expression associated with myocar-dial ischemia. FASEB J 2003; 17: 1105–7.
   Google Scholar
• Bibbins-Domingo K, Ansari M, Schiller NB, Massie B, Whooley MA. B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study. Circulation 2003; 108: 2987–92.
   Google Scholar
• Marie PY, Mertes PM, Hassan-Sebbag N, de Talence N, Djaballah K, Djaballah W, Friberg J, Olivier P, Karcher G, Zannad F, Bertrand A. Exercise release of cardiac natriuretic peptides is markedly enhanced when patients with coronary artery disease are treated medically by beta-blockers. J Am Coll Cardiol 2004; 43: 353–9.
   Google Scholar